Key Highlights

● Celularity's 8-K reports that Naveen Jain, founder and CEO of Viome Life Sciences, has been appointed a director.

● Director Diane Parks resigned, and both changes take effect after a waiting period tied to a Section 14(f) information statement.

● First-quarter 2026 revenue was $3,846 thousand versus $11,426 thousand a year earlier, with net income of $874 thousand.

● The 10-Q states there is substantial doubt about the company's ability to continue as a going concern.

Celularity Inc (NASDAQ:CELU) filed two documents with the U.S. Securities and Exchange Commission on September 29, 2026: a Form 8-K reporting a change on its board of directors, and a quarterly report on Form 10-Q for the quarter ended March 31, 2026. The 8-K says Naveen Jain, the founder and CEO of Viome Life Sciences Inc., has been appointed a director, while director Diane Parks has resigned. The 10-Q reports first-quarter revenue of $3.8 million and net income of $874 thousand.

The Board Change and Mr. Jain

The 8-K reports the change under Item 5.02. It says Mr. Jain was designated to the board through "board designation rights granted to certain investors" in the company's September 2026 financing, which the filing says was described in a Form 8-K filed on September 28, 2026. The appointment and Ms. Parks's resignation take effect at an "Effective Time," which the filing ties to the expiration of a waiting period following the filing of an information statement under Section 14(f) of the Securities Exchange Act. The 8-K itself does not give investor names, amounts or the terms of the designation rights, and refers readers to the earlier filing.

Ms. Parks resigned effective as of the Effective Time. The filing states: "Ms. Parks' decision to resign was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices."

According to the filing, Mr. Jain is founder and CEO of Viome Life Sciences Inc., described as "a health technology company that applies artificial intelligence and molecular data to personalized health and nutrition." He previously founded InfoSpace, Intelius, TalentWise and Moon Express. He will take part in the company's standard compensation arrangements for non-employee directors and is expected to enter the company's standard indemnification agreement. He has not been assigned to a committee and has no family relationships with other directors or officers.

The press release quotes Chairman and CEO Robert J. Hariri, M.D., Ph.D., as saying: "Naveen has devoted considerable energy to the pursuit of longer, healthier lives, and shares our belief in the significant potential of regenerative longevity." Mr. Jain is quoted as saying: "Healthcare is shifting from treating illness after symptoms appear to helping people take a more proactive role in their health."

What the 10-Q Reports

Total revenues for the first quarter of 2026 were $3,846 thousand, compared with $11,426 thousand a year earlier. Product sales were $866 thousand versus $9,018 thousand, and license, royalty and other revenue was $1,730 thousand versus $1,000 thousand. The operating loss was $10,133 thousand, against $10,486 thousand a year earlier.

Net income was $874 thousand, compared with a net loss of $19,754 thousand in the first quarter of 2025. The results include $12,159 thousand from the sale of New Jersey state tax loss benefits, which helped produce net income despite the operating loss. Cash and cash equivalents were $368 thousand at March 31, 2026.

Going Concern and Late Filing

The 10-Q states that "there is substantial doubt about the Company's ability to continue as a going concern," and reports an accumulated deficit of $990,609 thousand and a working capital deficit of $64,282 thousand. It also discloses that on May 27, 2026 the company received a notice from The Nasdaq Stock Market LLC of non-compliance with Nasdaq Listing Rule 5250(c)(1) because of the delay in filing the report.

The press release describes Celularity as a longevity-focused regenerative and cellular medicine company developing cell therapies from postpartum placenta, based in Florham Park, New Jersey.

When Jain Takes Celularity's Board Seat

The board change takes effect after the Section 14(f) waiting period expires, so a later filing will show when Mr. Jain is seated and Ms. Parks departs. The September 28, 2026 Form 8-K describes the financing behind the board designation rights, and the 10-Q reports results only through March 31, 2026.